Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study

被引：0
|
作者：
Vanessa Cristina de Oliveira Almeida
Daniel Dias Ribeiro
Karina Braga Gomes
Ana Lúcia Brunialti Godard
机构：
[1] Instituto de Ciências Biológicas,Department of General Biology
[2] Universidade Federal de Minas Gerais,Department of Molecular Genetics
[3] Hermes Pardini,Clinical Hospital
[4] Universidade Federal de Minas Gerais,Department of Clinical and Toxicological Analysis, Faculty of Pharmacy
[5] Universidade Federal de Minas Gerais,undefined
来源：
Molecular Diagnosis & Therapy | 2014年 / 18卷
关键词：
Warfarin; International Normalize Ratio; Warfarin Dose; Brazilian Population; UGT1A1 Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：675 / 683
页数：8
相关论文
共 50 条
  • [1] Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study
    de Oliveira Almeida, Vanessa Cristina
    Ribeiro, Daniel Dias
    Gomes, Karina Braga
    Brunialti Godard, Ana Lucia
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (06) : 675 - 683
  • [2] Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients
    Campos, Emilio Itamar de Freitas
    Gomes, Karina Braga
    Ribeiro, Daniel Dias
    Puurunen, Marja Kaarina
    Mourao, Aline deOliveira Magalhaes
    Ferreira, Isadora Goncalves
    Rocha, Manoel Otavio da Costa
    de Souza, Renan Pedra
    Martins, Maria Auxiliadora Parreiras
    PHARMACOGENOMICS, 2023, 24 (13) : 701 - 712
  • [3] Warfarin sensitivity and CYP2C9 and VKORC1 genes
    Bukaveckas, Bonny Lewis
    INFLAMMATION RESEARCH, 2007, 56 : S223 - S224
  • [4] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [5] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
  • [6] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Taisei Mushiroda
    Yozo Ohnishi
    Susumu Saito
    Atsushi Takahashi
    Yuka Kikuchi
    Shigeru Saito
    Hideki Shimomura
    Yasuhiko Wanibuchi
    Takao Suzuki
    Naoyuki Kamatani
    Yusuke Nakamura
    Journal of Human Genetics, 2006, 51 : 249 - 253
  • [7] Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients
    Oscanoa, Teodoro J.
    Guevara-Fujita, Maria L.
    Fujita, Ricardo M.
    Munoz-Paredes, Maria Y.
    Acosta, Oscar
    Romero-Ortuno, Roman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 769 - 775
  • [8] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Mushiroda, T
    Ohnishi, Y
    Saito, S
    Takahashi, A
    Kikuchi, Y
    Saito, S
    Shimomura, H
    Wanibuchi, Y
    Suzuki, T
    Kamatani, N
    Nakamura, Y
    JOURNAL OF HUMAN GENETICS, 2006, 51 (03) : 249 - 253
  • [9] Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients
    Li, Wenyan
    Zhao, Ping
    Chen, Liwen
    Lai, Xiaoyin
    Shi, Guohua
    Li, Longxuan
    Dong, Jing
    PHARMACOGENOMICS, 2020, 21 (02) : 101 - 110
  • [10] Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population
    Chowdhury, Zahid Sadek
    Shahjin, Farah
    Akter, Farhana
    Ahmed, Maizbha Uddin
    Islam, Mohammad Safiqul
    Bin Sayeed, Muhammad Shandaat
    Islam, Reazul
    Hasnat, Abul
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 30 (02) : 341 - 346
12345